GLP-1 obesity medications, such as Ozempic and Wegovy, play a significant role in weight management, but their effectiveness varies among individuals. Researchers at the University of Alberta are exploring the impact of energy metabolism and individual factors on the success of…
The shift from injectable GLP-1 medications to oral pills presents a significant opportunity to improve diabetes and obesity treatment accessibility, particularly in the Global So…
This article discusses the potential risks associated with discontinuing GLP-1 medications like Ozempic and Zepbound, as outlined by Dr. Frank Dumont. Patients may experience rene…
Dr. Ann Nainan from Medicspot provides a three-step plan to help individuals manage weight regain after discontinuing weight-loss injections such as Wegovy and Mounjaro. She empha…
As GLP-1 medications like Ozempic and Mounjaro gain popularity for managing diabetes and obesity, it's crucial to understand their nutritional implications. This article explores…
A recent study reveals that GLP-1 medications like Ozempic and Wegovy are changing the types of food people buy, leading to healthier choices. The research analyzed nearly 2 milli…
Recent developments in weight-loss medications highlight the potential of amylin-based drugs, which may offer effective weight management with fewer gastrointestinal side effects…
As the popularity of GLP-1 weight-loss medications like Ozempic and Wegovy rises, concerns emerge regarding their impact on brain health. Dr. Tommy Wood emphasizes that rapid weig…
A recent study published in the journal Childhood Obesity reveals that approximately 16.8% of children aged 10 to 17 who began treatment with GLP-1 receptor agonist medications de…
Emerging research highlights the potential of microdosing GLP-1 receptor agonists, such as semaglutide, during perimenopause to manage metabolic health. This approach may help add…
Research into GLP-1 medications, such as Ozempic and Wegovy, indicates they may play a role in reducing cancer risk by improving metabolic health, but the evidence remains mixed a…
Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
As 'Ozempic face' becomes a trending concern after weight loss from GLP-1 medications, surgeons adapt by offering innovative treatments to restore youthful facial volume and featu…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
Eli Lilly is targeting a revenue milestone of $100 billion by fiscal 2026, supported by strong growth in its incretin franchise and a bullish price target of $1,480. The company's…